Background In breast cancer, immunohistochemical assessment of proliferation using the
marker Ki67 has potential use in both research and clinical management. However, lack of …

Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which
has limited its clinical use. Our previous study found variability when laboratories used their …

Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles
in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) …

Ki67 expression has been a valuable prognostic variable in breast cancer, but has not seen
broad adoption due to lack of standardization between institutions. Automation could …

Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple
potential uses in breast cancer, but an unacceptable level of interlaboratory variability has …

Aims Vulvar squamous cell carcinoma ( VSCC ) can be subdivided by human papillomavirus
( HPV ) status into two clinicopathological entities. Studies on the prognostic significance of …

The nuclear proliferation biomarker Ki67 has potential prognostic, predictive, and monitoring
roles in breast cancer. Unacceptable between-laboratory variability has limited its clinical …

Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance
due to inter-laboratory variability. Here we tested an open source and calibrated automated …

Purpose Alterations to mismatch repair (MMR) pathways are a known cause of cancer,
particularly colorectal and endometrial carcinomas. Recently, checkpoint inhibitors have been …

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an
important tumour suppressor role, and is considered prognostic in several malignancies. …